Alpha 2.0
Login Register
» Authors » Vanessa Priesner

Vanessa Priesner

Explore the profile of Vanessa Priesner including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 7
Citations 542
Followers 0
Related Specialties
General Medicine
Biology
Microbiology
Top 10 Co-Authors
Clara Lehmann
Isabelle Suarez
Gerd Fatkenheuer
Norma Jung
Jan Rybniker
Max Augustin
Jakob J Malin
Michael Hallek
Melanie Stecher
Philipp Schommers
Published In
Nat Commun
Infection
Medicine (Baltimore)
Euro Surveill
Dtsch Med Wochenschr
Affiliations
Soon will be listed here.
Recent Articles
1.
Providing care in isolation while awaiting SARS-CoV-2 test results: Considering differential diagnoses and avoiding anchoring bias
Schmidt-Hellerau K, Meyer-Schwickerath C, Paul G, Augustin M, Priesner V, Rybniker J, et al.
Medicine (Baltimore) . 2021 Aug; 100(30):e26720. PMID: 34397706
Isolation of confirmed or suspected coronavirus disease 2019 (COVID-19) cases is essential but, as symptoms of COVID-19 are non-specific and test results not immediately available, case identification at admission remains...
2.
Post-COVID syndrome in non-hospitalised patients with COVID-19: a longitudinal prospective cohort study
Augustin M, Schommers P, Stecher M, Dewald F, Gieselmann L, Gruell H, et al.
Lancet Reg Health Eur . 2021 May; 6:100122. PMID: 34027514
Background: While the leading symptoms during coronavirus disease 2019 (COVID-19) are acute and the majority of patients fully recover, a significant fraction of patients now increasingly experience long-term health consequences....
3.
[New developments in outpatient parenteral antibiotic therapy (OPAT)]
Terhalle E, Jung N, Stegemann M, Priesner V, Lehmann C, Schmiedel S
Dtsch Med Wochenschr . 2020 Nov; 145(23):1688-1694. PMID: 33202453
Long term intravenous antibiotic therapy is required for the treatment of selected infections. Outpatient parenteral antibiotic therapy (OPAT) allows patients who require intravenous treatment to be treated outside of the...
4.
Plasma interferon-γ-inducible protein 10 (IP-10) levels correlate with disease severity and paradoxical reactions in extrapulmonary tuberculosis
Suarez I, Rohr S, Stecher M, Lehmann C, Winter S, Jung N, et al.
Infection . 2020 Nov; 49(3):437-445. PMID: 33140838
Background: With 1.5 million deaths worldwide in 2018, tuberculosis (TB) remains a major global public health problem. While pulmonary TB (PTB) is the most common manifestation, the proportion of extrapulmonary...
5.
Remdesivir against COVID-19 and Other Viral Diseases
Malin J, Suarez I, Priesner V, Fatkenheuer G, Rybniker J
Clin Microbiol Rev . 2020 Oct; 34(1). PMID: 33055231
Patients and physicians worldwide are facing tremendous health care hazards that are caused by the ongoing severe acute respiratory distress syndrome coronavirus 2 (SARS-CoV-2) pandemic. Remdesivir (GS-5734) is the first...
6.
Rapid response infrastructure for pandemic preparedness in a tertiary care hospital: lessons learned from the COVID-19 outbreak in Cologne, Germany, February to March 2020
Augustin M, Schommers P, Suarez I, Koehler P, Gruell H, Klein F, et al.
Euro Surveill . 2020 Jun; 25(21). PMID: 32489176
The coronavirus disease (COVID-19) pandemic has caused tremendous pressure on hospital infrastructures such as emergency rooms (ER) and outpatient departments. To avoid malfunctioning of critical services because of large numbers...
7.
Overcoming EGFR-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors
Fassunke J, Muller F, Keul M, Michels S, Dammert M, Schmitt A, et al.
Nat Commun . 2018 Nov; 9(1):4655. PMID: 30405134
The emergence of acquired resistance against targeted drugs remains a major clinical challenge in lung adenocarcinoma patients. In a subgroup of these patients we identified an association between selection of...